| ○種別 (必須): | □ | 学術論文 (審査論文)
| [継承] |
| ○言語 (必須): | □ | 英語
| [継承] |
| ○招待 (推奨): |
| ○審査 (推奨): |
| ○カテゴリ (推奨): |
| ○共著種別 (推奨): |
| ○学究種別 (推奨): |
| ○組織 (推奨): |
| ○著者 (必須): | 1. | (英) Amr Selim Ahmed Ali Abu Lila (日) (読) あむる せりむ あはめど あり あぶ りら
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): | □ | ****
| [ユーザ] |
| [継承] |
| 2. | (英) Katoh Chihiro (日) 加藤 千尋 (読) かとう ちひろ
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): | □ | ****
| [ユーザ] |
| [継承] |
| 3. | (英) Fukushima M (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 4. | (英) Huang C (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 5. | (英) Wada H (日) (読)
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| 6. | 石田 竜弘 ([徳島大学.大学院医歯薬学研究部.薬学域.薬科学部門.生命薬学系.薬物動態制御学]/[徳島大学.大学院医歯薬学研究部.薬学域.連携研究部門(薬学域).寄附講座系(薬学域).がん細胞と代謝学]/[徳島大学.大学産業院])
| ○役割 (任意): |
| ○貢献度 (任意): |
| ○学籍番号 (推奨): |
| [継承] |
| ○題名 (必須): | □ | (英) Downregulation of thymidylate synthase by RNAi molecules enhances the antitumor effect of pemetrexed in an orthotopic malignant mesothelioma xenograft mouse model (日)
| [継承] |
| ○副題 (任意): |
| ○要約 (任意): | □ | (英) Malignant pleural mesothelioma (MPM) is an incurable cancer with an increasing incidence. Currently, pemetrexed (PMX)-based chemotherapy is the mainstay of chemotherapy for MPM, however, the outcome of PMX-based chemotherapy in patients with MPM is dismal. RNA interference (RNAi) technology has been considered as an effective tool to substantially enhance the therapeutic efficacy of chemotherapeutic agents in many preclinical and clinical settings. In this study, therefore, we investigated whether non-viral anti-thymidylate synthase RNAi embedded liposome (TS shRNA lipoplex) would effectively guide the downregulation of TS in human malignant mesothelioma MSTO-211H cells. Consequently, it enhanced the antitumor effect of PMX both in vitro and in vivo. TS shRNA effectively enhanced the in vitro cell growth inhibition upon treatment with PMX via downregulating TS expression in the MSTO-211H cell line. In in vivo orthotopic tumor model, the combined treatment of PMX and TS shRNA lipoplex efficiently combated the progression of orthotopic thoracic tumors and as a result prolonged mouse survival, compared to each single treatment. Our findings emphasize the pivotal relevance of RNAi as an effective tool for increasing the therapeutic efficacy of PMX, a cornerstone in the treatment regimens of MPM, and thereby, raising the possibility for the development of a novel therapeutic strategy, combination therapy of TS-shRNA and PMX, that can surpass many of the currently applied, but less effective, therapeutic regimens against lethal MPM. (日)
| [継承] |
| ○キーワード (推奨): |
| ○発行所 (推奨): |
| ○誌名 (必須): | □ | International Journal of Oncology (International Center for Cancer Research)
(pISSN: 1019-6439, eISSN: 1791-2423)
| ○ISSN (任意): | □ | 1791-2423
ISSN: 1019-6439
(pISSN: 1019-6439, eISSN: 1791-2423) Title: International journal of oncologyTitle(ISO): Int J OncolPublisher: Spandidos Publications (NLM Catalog)
(Scopus)
(CrossRef)
(Scopus information is found. [need login]) | [継承] |
| [継承] |
| ○巻 (必須): | □ | 48
| [継承] |
| ○号 (必須): | □ | 4
| [継承] |
| ○頁 (必須): | □ | 1399 1407
| [継承] |
| ○都市 (任意): |
| ○年月日 (必須): | □ | 西暦 2016年 4月 初日 (平成 28年 4月 初日)
| [継承] |
| ○URL (任意): |
| ○DOI (任意): | □ | 10.3892/ijo.2016.3367 (→Scopusで検索)
| [継承] |
| ○PMID (任意): | □ | 26847426 (→Scopusで検索)
| [継承] |
| ○CRID (任意): |
| ○Scopus (任意): |
| ○researchmap (任意): |
| ○評価値 (任意): |
| ○被引用数 (任意): |
| ○指導教員 (推奨): |
| ○備考 (任意): | 1. | (英) Article.ELocationID: 10.3892/ijo.2016.3367 (日)
| [継承] |
| 2. | (英) Article.PublicationTypeList.PublicationType: Journal Article (日)
| [継承] |
| 3. | (英) Article.PublicationTypeList.PublicationType: Research Support, Non-U.S. Gov't (日)
| [継承] |